TRANSTHERA-B (02617) Enters Project Collaboration with Neurocrine

Stock News

Nov 03

TRANSTHERA-B (02617) announced that Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has entered into a royalty-bearing patent transfer and research collaboration agreement with the company to develop NLRP3 inhibitors for treating various diseases (the Agreement). Under the Agreement, Neurocrine is granted exclusive rights to develop, manufacture, and commercialize NLRP3 inhibitors from TRANSTHERA’s NLRP3 drug platform outside Greater China, while the company retains rights for development, manufacturing, and commercialization within Greater China (Mainland China, Hong Kong, Taiwan, and Macau).

The company is entitled to receive an upfront payment and may receive additional milestone payments tied to Neurocrine’s development and commercialization progress, including R&D and sales milestones. The total potential value of the Agreement is $881.5 million. The Agreement also includes a research collaboration between the parties to further advance NLRP3-related technologies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1131237438"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131237438\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131237438?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131237438","market":"sg","top_or_hot":-1,"title":"TRANSTHERA-B (02617) Enters Project Collaboration with Neurocrine","media":"Stock News","content":"<p>TRANSTHERA-B (02617) announced that Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has entered into a royalty-bearing patent transfer and research collaboration agreement with the company to develop NLRP3 inhibitors for treating various diseases (the Agreement). Under the Agreement, Neurocrine is granted exclusive rights to develop, manufacture, and commercialize NLRP3 inhibitors from TRANSTHERA’s NLRP3 drug platform outside Greater China, while the company retains rights for development, manufacturing, and commercialization within Greater China (Mainland China, Hong Kong, Taiwan, and Macau).</p>\n<p>The company is entitled to receive an upfront payment and may receive additional milestone payments tied to Neurocrine’s development and commercialization progress, including R&D and sales milestones. The total potential value of the Agreement is $881.5 million. The Agreement also includes a research collaboration between the parties to further advance NLRP3-related technologies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TRANSTHERA-B (02617) Enters Project Collaboration with Neurocrine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTRANSTHERA-B (02617) Enters Project Collaboration with Neurocrine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-03 08:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TRANSTHERA-B (02617) announced that Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has entered into a royalty-bearing patent transfer and research collaboration agreement with the company to develop NLRP3 inhibitors for treating various diseases (the Agreement). Under the Agreement, Neurocrine is granted exclusive rights to develop, manufacture, and commercialize NLRP3 inhibitors from TRANSTHERA’s NLRP3 drug platform outside Greater China, while the company retains rights for development, manufacturing, and commercialization within Greater China (Mainland China, Hong Kong, Taiwan, and Macau).</p>\n<p>The company is entitled to receive an upfront payment and may receive additional milestone payments tied to Neurocrine’s development and commercialization progress, including R&D and sales milestones. The total potential value of the Agreement is $881.5 million. The Agreement also includes a research collaboration between the parties to further advance NLRP3-related technologies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1131237438","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131237438","pubTimestamp":1762129213,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TRANSTHERA-B (02617) announced that Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has entered into a royalty-bearing patent transfer and research collaboration agreement with the company to develop...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B","BK1161":"生物科技"},"translate_title":"TRANSTHERA-B(02617)与Neurocrine达成项目合作","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"TRANSTHERA-B (02617) announced that Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has entered into a royalty-bearing patent transfer and research collaboration agreement with the company to develop NLRP3 inhibitors for treating various diseases (the Agreement). Under the Agreement, Neurocrine is granted exclusive rights to develop, manufacture, and commercialize NLRP3 inhibitors from TRANSTHERA’s NLRP3 drug platform outside Greater China, while the company retains rights for development, manufacturing, and commercialization within Greater China (Mainland China, Hong Kong, Taiwan, and Macau).\nThe company is entitled to receive an upfront payment and may receive additional milestone payments tied to Neurocrine’s development and commercialization progress, including R&D and sales milestones. The total potential value of the Agreement is $881.5 million. The Agreement also includes a research collaboration between the parties to further advance NLRP3-related technologies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}